Garnet Biotherapeutics, Inc.
Records under this name other than the patents Garnet Biotherapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 6 of 6 · Back to Garnet Biotherapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,969,977 | Cell populations which co-express CD49c and CD90 Lapsed on the fee record Ended May 15, 2026 · USPTO record | Lapsed on the fee record | Ended May 15, 2026 | USPTO record |
| US 9,969,980 | Cell populations which co-express CD49c and CD90 Lapsed on the fee record Ended May 15, 2026 · USPTO record | Lapsed on the fee record | Ended May 15, 2026 | USPTO record |
| US 8,486,696 | Cell populations which co-express CD49c and CD90 Lapsed on the fee record Ended Jul 16, 2025 · USPTO record | Lapsed on the fee record | Ended Jul 16, 2025 | USPTO record |
| US 9,556,467 | Methods of ganglioside production Lapsed on the fee record Ended Jan 31, 2025 · USPTO record | Lapsed on the fee record | Ended Jan 31, 2025 | USPTO record |
| US 8,354,370 | Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders Lapsed on the fee record Ended Jan 15, 2025 · USPTO record | Lapsed on the fee record | Ended Jan 15, 2025 | USPTO record |
| US 10,351,826 | Cell populations which co-express CD49c and CD90 Lapsed on the fee record Ended Jul 16, 2023 · USPTO record | Lapsed on the fee record | Ended Jul 16, 2023 | USPTO record |